The Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size in the 7MM was ~USD 1,843 million in 2025, and expected to grow with a CAGR of 7.6 % by 2036, estimates DelveInsight

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Inflammatory Demyelinating Polyneuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Chronic Inflammatory Demyelinating Polyneuropathy Market with DelveInsight's In-Depth Report @ Chronic Inflammatory Demyelinating Polyneuropathy Market Size- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report
• On May 15, 2026- Grifols Therapeutics LLC announced a study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people with CIDP.
• On May 13, 2026- Immunovant Sciences GmbH initiated a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP. This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Imeroprubart in adult participants with active CIDP.
• On May 13, 2026- Dianthus Therapeutics conducted a Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
• In 2023, the US accounted for the highest diagnosed prevalent cases of CIDP with approximately 30,230 cases, which are expected to increase by 2036.
• Among EU4 and the UK, the UK had the highest diagnosed prevalent cases of CIDP, with nearly 3,250 cases in 2023, followed by Germany with around 3,174 cases. In contrast, Spain has the lowest number, with nearly 1,691 cases.
• In 2023, Japan accounted for approximately 2,045 diagnosed prevalent cases of CIDP which are expected to increase by 2036.
• In 2023, among the subtype-specific cases of CIDP, the US accounted for approximately 15,417 cases for typical CIDP and 14,813 cases for atypical CIDP.
• In 2023, Germany had approximately 2,380 males and 793 females diagnosed with CIDP.
• In 2023, the diagnosed prevalent cases of CIDP across the age groups 0-19 years, 20-39 years, 40-59 years, 60-79 years and 80 years and older were approximately 41, 82, 798, 900 and 225, respectively, in Japan.
• The leading Chronic Inflammatory Demyelinating Polyneuropathy Companies such as CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, among others.
• Promising Chronic Inflammatory Demyelinating Polyneuropathy Therapies such as Riliprubart, Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Efgartigimod PH20 SC, SAR445088 (IV), and others.

Stay ahead in the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market with DelveInsight's Strategic Report @ Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation in the 7MM
• Chronic Inflammatory Demyelinating Polyneuropathy Diagnosed Prevalent Cases
• Chronic Inflammatory Demyelinating Polyneuropathy Gender-specific Diagnosed Prevalent Cases
• Chronic Inflammatory Demyelinating Polyneuropathy Age-specific Diagnosed Prevalent Cases
• Chronic Inflammatory Demyelinating Polyneuropathy Clinical Subtype-specific Diagnosed Prevalent Cases
• Chronic Inflammatory Demyelinating Polyneuropathy Refractory Cases

Download the report to understand which factors are driving Chronic Inflammatory Demyelinating Polyneuropathy epidemiology trends @ Chronic Inflammatory Demyelinating Polyneuropathy Prevalence- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Chronic Inflammatory Demyelinating Polyneuropathy Drugs
• HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda
HYQVIA is an immunostimulant combining human immunoglobulin (IG 10%) with recombinant human hyaluronidase, enabling SC for easier administration. This treatment offers a convenient alternative to IVIg by allowing larger-volume, less frequent SC due to enhanced absorption. HYQVIA modulates the immune system to reduce autoimmune damage to the nerves in CIDP. In January 2024, the US FDA approved HYQVIA for the maintenance treatment of CIDP in adults. The European Commission also approved it for the same purpose, and the UK's MHRA granted approval in March 2024. Takeda filed for approval in Japan in August 2024.

• VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx
VYVGART HYTRULO is a coformulation of efgartigimod alfa and recombinant human hyaluronidase, designed to enhance SC absorption. It works by reducing autoantibodies implicated in CIDP through inhibition of the FcRn receptor. Approved by the US FDA in June 2024, it received orphan drug designation for CIDP in 2021. This therapy offers a convenient option for maintaining remission via SC administration.

• GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda
GAMMAGARD LIQUID/KIOVIG is a ready-to-use IV formulation of IVIg derived from human plasma, offering a broad spectrum of antibodies. It works by modulating the immune system, reducing inflammation, and preventing further nerve damage in CIDP. Clinical studies have shown its effectiveness in improving muscle strength and functional ability, helping manage symptoms and maintain long-term stability. It was approved by the US FDA in January 2024 for adults with CIDP. In May 2019, KIOVIG was also approved in the EU for treating CIDP in adults, children, and adolescents (0-18 years).

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs
• Riliprubart (SAR445088): Sanofi
Riliprubart (SAR445088) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. By blocking C1s, riliprubart has the potential to inhibit key inflammatory mechanisms that drive demyelination and axonal damage in CIDP. Riliprubart has convenient subcutaneous route of administration. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of CIDP.

• Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences
Batoclimab is a human monoclonal antibody directed against the Neonatal Crystallizable Fragment Receptor (FcRn), with potential immunomodulating activity. Upon administration, batoclimab targets and binds to FcRn at the Immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, batoclimab blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes. Immunovant reported topline results in March 2025 from its Phase IIb study of batoclimab in CIDP, showing meaningful improvements in disability scores during the initial 12-week period. Patients with deeper reductions in IgG levels demonstrated higher responder rates.

Get In-Depth Knowledge on Chronic Inflammatory Demyelinating Polyneuropathy Market Trends and Forecasts with DelveInsight @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Inflammatory Demyelinating Polyneuropathy Drugs Market Landscape
Chronic inflammatory demyelinating polyneuropathy treatment primarily involves corticosteroids as the first-line therapy, often combined with immunosuppressants like methotrexate or azathioprine for patients who do not respond adequately. In cases of severe or resistant disease, IVIg may be beneficial, and biologics such as rituximab can be considered for some cases. Emerging therapies include riliprubart (SAR445088), nipocalimab (JNJ-80202135), and batoclimab (HL161).
• Riliprubart (SAR445088), is an investigational IgG4 humanized monoclonal antibody designed to selectively block activated C1s, a key component of the classical complement pathway in the innate immune system.
• Nipocalimab (JNJ-80202135) is an investigational, high-affinity monoclonal antibody administered IV as an FcRn inhibitor. It is currently in Phase II/III clinical trials for CIDP.
• Batoclimab (HL161) a subcutaneous anti-FcRn antibody. Batoclimab specifically inhibits FcRn, promoting the breakdown of IgG and reducing its levels in circulation. It is being developed collaboratively by Immunovant, with HanAll Biopharma leading efforts to expand its indications. It targets rare autoimmune diseases by reducing IgG levels.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Landscape
The treatment landscape for CIDP has advanced with a multi-faceted approach, combining medications, and supportive care. Corticosteroids, such as prednisone and dexamethasone, are often the initial treatment. While they are effective in inducing remission, they carry a high risk of significant long-term side effects, including osteoporosis, weight gain, and increased susceptibility to infections. These adverse effects often necessitate combination therapies with steroid-sparing agents, which may not be universally effective.

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook
Chronic inflammatory demyelinating polyneuropathy, though classified as a rare disease, has gained increasing recognition in recent years. This is largely due to improvements in diagnostic techniques, greater awareness among healthcare professionals, and a deeper understanding of the condition. Management of CIDP typically involves a combination of pharmacological therapies and supportive interventions, with the primary objectives to suppress inflammation, modulate immune responses, and improve motor and sensory function. Plasma exchange has shown short-term efficacy in removing harmful autoantibodies and improving symptoms. However, it is an invasive procedure that requires highly specialized centers and trained personnel, limiting its accessibility, IVIg has become the gold standard due to its demonstrated efficacy in long-term disease control and symptom improvement. Despite this, IVIg is costly, time-consuming, and heavily reliant on donor plasma, raising concerns about its long-term availability.

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market
• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Chronic Inflammatory Demyelinating Polyneuropathy Companies- CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, among others.
• Chronic Inflammatory Demyelinating Polyneuropathy Therapies- Riliprubart, Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Efgartigimod PH20 SC, SAR445088 (IV), and others.
• Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics: Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Barriers
• Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight's Comprehensive Chronic Inflammatory Demyelinating Polyneuropathy Market Report @ Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Barriers- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction
3. Chronic Inflammatory Demyelinating Polyneuropathy Market Overview at a Glance
4. Chronic Inflammatory Demyelinating Polyneuropathy Methodology
5. Executive Summary
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
9. Diagnostic and Treatment Guidelines for Chronic Inflammatory Demyelinating Polyneuropathy
10. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs
11. Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey
12. Approved Therapies
13. Chronic Inflammatory Demyelinating Polyneuropathy Emerging Therapies
14. Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis
15. Chronic Inflammatory Demyelinating Polyneuropathy KOL Views
16. Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers
17. Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers
18. Chronic Inflammatory Demyelinating Polyneuropathy SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.